Literature DB >> 23097128

Effects of hypertrophy and fibrosis on regional and global functional heterogeneity in hypertrophic cardiomyopathy.

Sung-A Chang1, Sang-Chol Lee, Yeon Hyeon Choe, Hye-Jin Hahn, Shin Yi Jang, Sung-Ji Park, Jin-Oh Choi, Seung Woo Park, Jae K Oh.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a disease that typically has heterogeneous hypertrophy and dysfunction of the myocardium. Cardiac magnetic resonance imaging (CMR) can be used to accurately assess ventricular wall thickness and regional fibrosis. We investigated the effects of hypertrophy and fibrosis on the heterogeneity of regional and global myocardial function in HCM. Forty patients who were diagnosed with HCM were consecutively enrolled. Echocardiography and CMR with delayed hyper-enhancement imaging (DHE) was performed for each patient. Left ventricular (LV) regional and global longitudinal strain (SL(R) and SL(G)) were obtained by two-dimensional speckle tracking method on echocardiography. With CMR, regional myocardial wall thickness was measured, and the amount of DHE was calculated semi-quantitatively in each segment. Overall, 720 segments were analyzed. SL(R) was significantly decreased in the hypertrophied segments (thickness > 11 mm) and segments with DHE (P < 0.001). SL(R) was correlated with myocardial wall thickness (r = 0.47, P = 0.001) and amount of regional DHE (r = 0.39, P < 0.001). On multivariate analysis, regional LV wall thickness and amount of DHE were the only independent determinants of SL(R). SL(G) was associated with LV diastolic functional parameters in echocardiography, total DHE volume, and LV mass index. Total DHE volume and LV mass index were independent determinants of SL(G) on multivariate analysis. The extent of regional myocardial fibrosis is associated with regional myocardial function independently of morphological changes of the myocardium, and the correlation extended to global LV function. In this context, DHE may be a useful parameter to discover early myocardial dysfunction independently of LV hypertrophy.

Entities:  

Mesh:

Year:  2012        PMID: 23097128     DOI: 10.1007/s10554-012-0141-2

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  21 in total

1.  Upstream high-dose tirofiban does not reduce myocardial infarct size in patients undergoing primary percutaneous coronary intervention: a magnetic resonance imaging pilot study.

Authors:  Young Bin Song; Joo-Yong Hahn; Hyeon-Cheol Gwon; Jun Hyung Kim; Sang Yeub Lee; Yeon Hyeon Choe; Seung-Hyuk Choi; Jin-Ho Choi; Sang Hoon Lee
Journal:  Clin Cardiol       Date:  2009-06       Impact factor: 2.882

Review 2.  Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy (1).

Authors:  B J Maron; R O Bonow; R O Cannon; M B Leon; S E Epstein
Journal:  N Engl J Med       Date:  1987-03-26       Impact factor: 91.245

3.  Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction.

Authors:  Chung-Lieh Hung; Anil Verma; Hajime Uno; Sung-Hee Shin; Mikhail Bourgoun; Amira H Hassanein; John J McMurray; Eric J Velazquez; Lars Kober; Marc A Pfeffer; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2010-11-23       Impact factor: 24.094

4.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

5.  Impact of impaired myocardial deformations on exercise tolerance and prognosis in patients with asymptomatic aortic stenosis.

Authors:  Stéphane Lafitte; Matthieu Perlant; Patricia Reant; Karim Serri; Herve Douard; Anthony DeMaria; Raymond Roudaut
Journal:  Eur J Echocardiogr       Date:  2008-11-07

6.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy.

Authors:  Paola Melacini; Cristina Basso; Annalisa Angelini; Chiara Calore; Fabiana Bobbo; Barbara Tokajuk; Nicoletta Bellini; Gessica Smaniotto; Mauro Zucchetto; Sabino Iliceto; Gaetano Thiene; Barry J Maron
Journal:  Eur Heart J       Date:  2010-05-31       Impact factor: 29.983

7.  Association between regional ventricular function and myocardial fibrosis in hypertrophic cardiomyopathy assessed by speckle tracking echocardiography and delayed hyperenhancement magnetic resonance imaging.

Authors:  Zoran B Popović; Deborah H Kwon; Micky Mishra; Adisai Buakhamsri; Neil L Greenberg; Maran Thamilarasan; Scott D Flamm; James D Thomas; Harry M Lever; Milind Y Desai
Journal:  J Am Soc Echocardiogr       Date:  2008-12       Impact factor: 5.251

8.  Diastolic function in hypertrophic cardiomyopathy: relation to exercise capacity.

Authors:  P Nihoyannopoulos; G Karatasakis; M Frenneaux; W J McKenna; C M Oakley
Journal:  J Am Coll Cardiol       Date:  1992-03-01       Impact factor: 24.094

9.  Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis.

Authors:  Jun Koyama; Patricia A Ray-Sequin; Rodney H Falk
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

10.  A novel feature-tracking echocardiographic method for the quantitation of regional myocardial function: validation in an animal model of ischemia-reperfusion.

Authors:  Bahar Pirat; Dirar S Khoury; Craig J Hartley; Les Tiller; Liyun Rao; Daryl G Schulz; Sherif F Nagueh; William A Zoghbi
Journal:  J Am Coll Cardiol       Date:  2008-02-12       Impact factor: 24.094

View more
  10 in total

1.  Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy.

Authors:  Rocio Hinojar; Jose Luis Zamorano; MªAngeles Fernández-Méndez; Amparo Esteban; Maria Plaza-Martin; Ariana González-Gómez; Alejandra Carbonell; Luis Miguel Rincón; Jose Julio Jiménez Nácher; Covadonga Fernández-Golfín
Journal:  Int J Cardiovasc Imaging       Date:  2019-01-31       Impact factor: 2.357

2.  Global cardiac alterations detected by speckle-tracking echocardiography in Fabry disease: left ventricular, right ventricular, and left atrial dysfunction are common and linked to worse symptomatic status.

Authors:  Daniel A Morris; Daniela Blaschke; Sima Canaan-Kühl; Alice Krebs; Gesine Knobloch; Thula C Walter; Wilhelm Haverkamp
Journal:  Int J Cardiovasc Imaging       Date:  2014-10-15       Impact factor: 2.357

3.  The prognostic value of standardized reference values for speckle-tracking global longitudinal strain in hypertrophic cardiomyopathy.

Authors:  Gregory R Hartlage; Jonathan H Kim; Patrick T Strickland; Alan C Cheng; Nima Ghasemzadeh; Maria A Pernetz; Stephen D Clements; B Robinson Williams
Journal:  Int J Cardiovasc Imaging       Date:  2015-01-14       Impact factor: 2.357

Review 4.  Fibrosis in hypertrophic cardiomyopathy: role of novel echo techniques and multi-modality imaging assessment.

Authors:  Efstathios D Pagourelias; Georgios M Alexandridis; Vassilios P Vassilikos
Journal:  Heart Fail Rev       Date:  2021-05-15       Impact factor: 4.214

Review 5.  Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail.

Authors:  Summer Hassan; Carolyn J Barrett; David J Crossman
Journal:  Biophys Rev       Date:  2020-07-23

Review 6.  Myocardial hypertrophy and its role in heart failure with preserved ejection fraction.

Authors:  Frank R Heinzel; Felix Hohendanner; Ge Jin; Simon Sedej; Frank Edelmann
Journal:  J Appl Physiol (1985)       Date:  2015-07-16

7.  Feasibility of radial and circumferential strain analysis using 2D speckle tracking echocardiography in cats.

Authors:  Hiroshi Takano; Tomomi Isogai; Takuma Aoki; Yoshito Wakao; Yoko Fujii
Journal:  J Vet Med Sci       Date:  2014-11-06       Impact factor: 1.267

8.  Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology.

Authors:  Rudolf A de Boer; Gilles De Keulenaer; Johann Bauersachs; Dirk Brutsaert; John G Cleland; Javier Diez; Xiao-Jun Du; Paul Ford; Frank R Heinzel; Kenneth E Lipson; Theresa McDonagh; Natalia Lopez-Andres; Ida G Lunde; Alexander R Lyon; Piero Pollesello; Sanjay K Prasad; Carlo G Tocchetti; Manuel Mayr; Joost P G Sluijter; Thomas Thum; Carsten Tschöpe; Faiez Zannad; Wolfram-Hubertus Zimmermann; Frank Ruschitzka; Gerasimos Filippatos; Merry L Lindsey; Christoph Maack; Stephane Heymans
Journal:  Eur J Heart Fail       Date:  2019-02-04       Impact factor: 15.534

9.  Feasibility of one breath-hold cardiovascular magnetic resonance compressed sensing cine for left ventricular strain analysis.

Authors:  Xiaorong Chen; Jiangfeng Pan; Yi Hu; Hongjie Hu; Yonghao Pan
Journal:  Front Cardiovasc Med       Date:  2022-08-12

10.  Early detection of myocardial dysfunction using two-dimensional speckle tracking echocardiography in a young cat with hypertrophic cardiomyopathy.

Authors:  Ryohei Suzuki; Yohei Mochizuki; Hiroki Yoshimatsu; Ayaka Niina; Takahiro Teshima; Hirotaka Matsumoto; Hidekazu Koyama
Journal:  JFMS Open Rep       Date:  2018-02-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.